Virax Biolabs (VRAX) director files initial insider ownership report

Rhea-AI Filing Summary

Virax Biolabs Group Ltd director Miller Iain David filed a Form 3, which is an initial statement of beneficial ownership. This filing records his starting equity position as an insider of the company but does not report any stock purchases, sales, option exercises, or other transactions.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Miller Iain David

(Last) (First) (Middle)

BIOCITY GLASGOW BO'NESS ROAD

NEWHOUSE LANARKSHIRE

(Street)

MOTHERWELL LANARKSHIRE UNITED KINGDOM ML1 5UH

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Virax Biolabs Group Ltd [ VRAX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Iain Miller	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Virax Biolabs (VRAX) Form 3 filing by Miller Iain David mean?

The Form 3 filing shows that Miller Iain David is an insider of Virax Biolabs Group Ltd. It records his initial beneficial ownership position but does not include any stock purchases, sales, or option exercises at this time.

Did Miller Iain David buy or sell Virax Biolabs (VRAX) shares in this Form 3?

No, this Form 3 does not report any share purchases or sales. It serves only as an initial statement of beneficial ownership for Miller Iain David as a director of Virax Biolabs Group Ltd.

What type of insider is Miller Iain David at Virax Biolabs (VRAX)?

Miller Iain David is identified as a director of Virax Biolabs Group Ltd. The Form 3 confirms his status as a reporting insider but does not describe him as an officer or ten percent owner.

Does the Virax Biolabs (VRAX) Form 3 show any derivative securities or options?

No derivative securities or options are listed in this Form 3. The derivativeSummary and related transaction counts are all zero, indicating no options, warrants, or similar instruments are reported in this filing.

Is the Virax Biolabs (VRAX) Form 3 filing a major event for shareholders?

This Form 3 is a routine regulatory filing that records a director’s initial beneficial ownership. It does not disclose new transactions or financial results, so it is generally considered administrative rather than a major market-moving event.